Invitation from the conference chairs

Dear Colleague,

We would like to invite you to join us at The Lancet Neurology Conference ‘Preclinical neurodegenerative disease: towards prevention and early diagnosis’, to be held in London, UK, on October 19−21, 2016.

The clinical symptoms of a neurodegenerative disease arise once the underlying pathological process is already advanced in the brain, and sometimes decades after the onset of neuronal damage. By the time the patient receives a diagnosis, it might be too late to intervene and modify the pathological state of the disease. Researchers are now focusing on preventing and stopping the pathological processes at an earlier, asymptomatic state. The ethical implications of this approach, involving counselling and treating healthy people at risk, are a matter of debate.

This conferenceaims to disseminate cutting-edge findings on preclinical neurodegenerative diseases—including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. The event will provide a unique platform for specialists to come together across disciplines for an authoritative discussion of the methodological, regulatory, and ethical considerations of research in people at asymptomatic states of neurodegenerative disease.

The event will also have a translational focus, exploring genetic susceptibility, epidemiology and risk factors, neuronal vulnerability, biomarkers and early diagnosis, and disease prevention in healthy individuals with both pharmacological and non-pharmacological interventions. Additionally, the programme will include poster presentations affording you an occasion to present your work to a broad audience of experts and key opinion leaders.

We hope you find the conference details on this website to be a persuasive reason to attend.

We look forward to seeing you in London.

Elena Becker-Barroso, Editor, The Lancet Neurology
John Hardy, Department of Molecular Neuroscience, University College London
Jonathan Rohrer, Dementia Research Centre, University College London
Sarah Tabrizi, Institute of Neurology, University College London

Supporting Publication
Organised by
 
  • Lancet Neurology
  • Elsevier
Silver Sponsor
 
Teva
Sponsors
 
AstraZeneca